About LysM and putative peptidoglycan-binding domain-containing protein 4
LysM and putative peptidoglycan-binding domain-containing protein 4 (LYSMD4) is a protein
from Homo sapiens identified by UniProt accession
Q5XG99, 296 residues long.
MolForge cross-references it against 0 known binders and
18 disease associations.
Target properties
| Protein name | LysM and putative peptidoglycan-binding domain-containing protein 4 |
| UniProt accession | Q5XG99 |
| Gene | LYSMD4 |
| Organism | Homo sapiens |
| Length | 296 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (18)
Diseases linked to this target (Open Targets).
- vitamin D measurement · score 0.29
- cranial vault morphology measurement · score 0.28
- BMI-adjusted waist-hip ratio · score 0.21
- mean arterial pressure · score 0.14
- vital capacity · score 0.07
- body height · score 0.06
- systolic blood pressure · score 0.06
- forced expiratory volume · score 0.05
- body fat percentage · score 0.05
- sitting height measurement · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q5XG99-F1 | alphafold | PREDICTED | 62.43 | — |
Amino-acid sequence (296 residues)
MRHEELLTKT FQGPAVVCGT PTSHVYMFKN GSGDSGDSSE EESHRVVLRP RGKERHKSGV HQPPQAGAGD VVLLQRELAQ EDSLNKLALQ YGCKVADIKK VNNFIREQDL YALKSVKIPV RNHGILMETH KELKPLLSPS SETTVTVELP EADRAGAGTG AQAGQLMGFF KGIDQDIERA VQSEIFLHES YCMDTSHQPL LPAPPKTPMD GADCGIQWWN AVFIMLLIGI VLPVFYLVYF KIQASGETPN SLNTTVIPNG SMAMGTVPGQ APRLAVAVPA VTSADSQFSQ TTQAGS
Explore LysM and putative peptidoglycan-binding domain-containing protein 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets